Patents by Inventor John Christopher Castle
John Christopher Castle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220282322Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: ApplicationFiled: January 14, 2022Publication date: September 8, 2022Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Löwer, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
-
Publication number: 20220093209Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.Type: ApplicationFiled: November 30, 2021Publication date: March 24, 2022Inventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
-
Patent number: 11248264Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: GrantFiled: July 2, 2020Date of Patent: February 15, 2022Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SEInventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Löwer, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
-
Patent number: 11222711Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.Type: GrantFiled: May 7, 2014Date of Patent: January 11, 2022Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
-
Publication number: 20210164034Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: ApplicationFiled: July 2, 2020Publication date: June 3, 2021Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
-
Patent number: 10738355Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: GrantFiled: May 23, 2012Date of Patent: August 11, 2020Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech RNA Pharmaceuticals GmbHInventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
-
Publication number: 20200237885Abstract: Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer.Type: ApplicationFiled: January 9, 2020Publication date: July 30, 2020Inventors: Daniel Lewis Levey, John Christopher Castle, Robert Benjamin Stein, Jennifer Shanda Buell
-
Patent number: 10568948Abstract: Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer.Type: GrantFiled: May 13, 2016Date of Patent: February 25, 2020Assignee: AGENUS INC.Inventors: Daniel Lewis Levey, John Christopher Castle
-
Publication number: 20160331821Abstract: Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer.Type: ApplicationFiled: May 13, 2016Publication date: November 17, 2016Inventors: Daniel Lewis Levey, John Christopher Castle, Robert Benjamin Stein, Jennifer Shanda Buell
-
Publication number: 20160125129Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.Type: ApplicationFiled: May 7, 2014Publication date: May 5, 2016Applicants: BioNTech AG, TROMInventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
-
Publication number: 20140178438Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: ApplicationFiled: May 23, 2012Publication date: June 26, 2014Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf